Replies to post #24504 on Innovation Pharmaceuticals Inc (IPIX)

[tduggan]

Ultimately the market is going to depend on how many applications show safety and effectiveness in human trials. With combinations, that # could be quite large. If you review previous posts here, speculation tends to figure that when the company is showing indications in the 10-12 billion range (including sales of P for psoriasis and other possible autoimmune disorders) that all or part of the company will be sold off or partnered.

I have gone back and read all posts here and followed links since May 2011. I would recommend taking the time and doing the same.

Some of the contributors to zero in on are DrFeelgood, The Progressive, KarinCa, Keltoi, Govorchin, TOB, Umiak, JB3729 and many more. You can form your opinions as you follow along.

[edge]

You'll hear 200 next don't be surprised the carnage continues bearish sentiment techs rolling over negative momentum and accelerating no bottom in sight

[BonelessCat]

The fact is, no one knows what next fall will bring, and few posters here are equipped to make performance projections based on success and failure.

If I had time I'd go through my algorithm and crunch numbers, but here are the bottom lines I get:

After September:

Prurisol and Kevetrin both successful with high efficacy: $30-$50 a share pending the first deal.

Prurisol or Kevetrin high efficacy with one or the other inconclusive: $10-$15, pending the first deal for the successful one.

Prurisol and Kevetrin both inconclusive, but worth continuing for the next round of clinicals: $5

Both Prurisol and Kevetrin fail to provide efficacy: No bottom until a return to 10 cents.

One more comment, all the data you are looking for is now moot with both drugs entering or in trials. The only thing that counts now is how they perform in humans.